Koninklijke Philips N.V. (DE:PHIA)
NYSE:PHIA
Want to see DE:PHIA full AI Analyst Report?
PHIA Stock Chart & Stats
€24.00
€0.00(0.00%)
At close: 4:00 PM EDT
€24.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€18.90 - €27.60
Previous CloseN/A
Volume59.00
Average Volume (3M)18.00
Market Cap
€21.82B
Enterprise Value€27.61B
Total Cash (Recent Filing)€2.59B
Total Debt (Recent Filing)€8.11B
Price to Earnings (P/E)31.9
Beta0.90
Next Earnings
Jul 28, 2026EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.02
Shares Outstanding962,920,100
10 Day Avg. Volume30
30 Day Avg. Volume18
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)2.02
Price to Sales (P/S)1.24
P/FCF Ratio24.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.55
Revenue Forecast (FY)€18.07B
Bulls Say, Bears Say
Bulls Say
Recurring Services & Installed BasePhilips’ mix of capital equipment plus attached services, software and consumables creates a durable installed‑base flywheel. This generates higher‑margin, repeatable revenue, increases customer switching costs and stabilizes cash flows relative to one‑off equipment cycles, supporting medium‑term margin and revenue visibility.
Regulatory & Innovation MomentumA steady stream of regulatory approvals and new product launches (AI cardiac MR, spectral CT, helium‑free MR initiatives) reduces commercialization risk and strengthens Philips’ technology moat. Continuous regulatory wins accelerate clinical adoption, improve attach rates for software/services, and underpin sustainable equipment demand over the medium term.
Productivity & Margin RecoveryMaterial productivity delivery and observable margin expansion demonstrate structural cost discipline. On‑track savings toward a multi‑year €1.5bn target improve operating leverage, support management’s mid‑cycle margin ambitions and enhance free cash generation potential, strengthening balance‑sheet flexibility and funding for strategic reinvestment.
Bears Say
Unresolved Legal RiskOutstanding Respironics‑related proceedings represent a potentially material, unmodeled liability. Their exclusion from guidance creates persistent uncertainty around future earnings and cash flows, complicates capital allocation decisions and may constrain shareholder returns or M&A until the legal exposure is resolved or more clearly quantified.
Volatile Cash GenerationPhilips’ historical cash‑flow volatility—including negative operating/FCF years and a sharp 2025 FCF decline versus 2024—reduces confidence in sustainable internal funding. Variable FCF makes it harder to predict capacity for capex, R&D, services investments or discretionary returns, increasing reliance on disciplined balance‑sheet management.
China Procurement HeadwindsRising centralized procurement in China is structurally pressuring pricing and order conversion in key modalities (ultrasound, CT). Given China’s scale, persistent procurement‑driven pricing and longer decision cycles can limit equipment growth and margin recovery in diagnostic segments, dampening a significant market opportunity over the medium term.
PHIA FAQ
What was Koninklijke Philips N.V.’s price range in the past 12 months?
Koninklijke Philips N.V. lowest stock price was €18.90 and its highest was €27.60 in the past 12 months.
What is Koninklijke Philips N.V.’s market cap?
Koninklijke Philips N.V.’s market cap is €21.82B.
When is Koninklijke Philips N.V.’s upcoming earnings report date?
Koninklijke Philips N.V.’s upcoming earnings report date is Jul 28, 2026 which is in 67 days.
How were Koninklijke Philips N.V.’s earnings last quarter?
Koninklijke Philips N.V. released its earnings results on May 06, 2026. The company reported €0.232 earnings per share for the quarter, beating the consensus estimate of €0.198 by €0.034.
Is Koninklijke Philips N.V. overvalued?
According to Wall Street analysts Koninklijke Philips N.V.’s price is currently Overvalued.
Does Koninklijke Philips N.V. pay dividends?
Koninklijke Philips N.V. does not currently pay dividends.
What is Koninklijke Philips N.V.’s EPS estimate?
Koninklijke Philips N.V.’s EPS estimate is 0.36.
How many shares outstanding does Koninklijke Philips N.V. have?
Koninklijke Philips N.V. has 962,920,100 shares outstanding.
What happened to Koninklijke Philips N.V.’s price movement after its last earnings report?
Koninklijke Philips N.V. reported an EPS of €0.232 in its last earnings report, beating expectations of €0.198. Following the earnings report the stock price went up 2.68%.
Which hedge fund is a major shareholder of Koninklijke Philips N.V.?
Currently, no hedge funds are holding shares in DE:PHIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Koninklijke Philips Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:PHIA Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.69%
12-Months-Change
Fundamentals
Return on Equity
8.96%
Trailing 12-Months
Asset Growth
7.05%
Trailing 12-Months
Company Description
Koninklijke Philips N.V.
Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
PHIA Company Deck
PHIA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presented a constructive tone: Philips reported broad-based order and sales growth, margin expansion, strong productivity delivery, robust innovation and regulatory momentum, and meaningful balance sheet improvement. These positives were balanced against notable headwinds in China (centralized procurement), cost inflation (freight, components, plastics) and near-term margin timing effects from tariffs and inflation. Management reiterated full-year guidance (3%–4.5% comparable sales; 12.5%–13% adjusted EBITDA margin; EUR 1.3–1.5bn free cash flow) and emphasized mitigation actions (productivity, selective pricing, AI-enabled cost savings) while acknowledging geopolitical and legal uncertainties.View all DE:PHIA earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---